Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 331

1.

Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.

Kamble R, Wilson CS, Fassas A, Desikan R, Siegel DS, Tricot G, Anderson P, Sawyer J, Anaissie E, Barlogie B.

Leuk Lymphoma. 2005 Aug;46(8):1137-42.

PMID:
16085553
2.

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.

Bone Marrow Transplant. 1999 Sep;24(5):497-503.

3.

Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature.

Kim YJ, Kim SJ, Min K, Kim HY, Kim HJ, Lee YK, Zang DY.

Acta Haematol. 2008;120(2):108-11. doi: 10.1159/000165694. Epub 2008 Oct 29. Review.

PMID:
18957845
4.

Myelomatous pleural effusion: a case series in a single institution and literature review.

Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Suh C.

Korean J Lab Med. 2011 Oct;31(4):225-30. doi: 10.3343/kjlm.2011.31.4.225. Epub 2011 Oct 3. Review.

5.

A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.

Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R.

Respirology. 2004 Mar;9(1):66-9.

PMID:
14982604
6.

Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.

Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.

Cancer. 2007 Aug 15;110(4):824-9.

7.

Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.

Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.

8.

Myelomatous pleural effusion.

Ghosh S, Gopal R, Advani SH.

J Assoc Physicians India. 2006 Sep;54:738-9.

PMID:
17212026
9.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.

Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC).

Br J Haematol. 2007 Feb;136(4):615-23.

PMID:
17223915
11.

Prognostic significance of pleural fluid data in patients with malignant effusion.

Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, Porcel JM.

Eur J Intern Med. 2008 Jul;19(5):334-9. doi: 10.1016/j.ejim.2007.09.014. Epub 2007 Nov 8.

PMID:
18549935
12.

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

Drach J, Ackermann J, Fritz E, Krömer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H, Huber H.

Blood. 1998 Aug 1;92(3):802-9.

13.

High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.

Suguro M, Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.

Am J Hematol. 2000 Oct;65(2):132-5.

PMID:
10996830
14.

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.

Barlogie B, Smallwood L, Smith T, Alexanian R.

Ann Intern Med. 1989 Apr 1;110(7):521-5.

PMID:
2647015
15.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5.

16.

Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.

Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA.

Biol Blood Marrow Transplant. 2007 Sep;13(9):1066-72. Epub 2007 Jul 16.

17.

[Multiple myeloma--new therapeutic perspectives].

Skotnicki AB, Wolska-Smoleń T, Jurczyszyn A.

Przegl Lek. 1999;56 Suppl 1:67-72. Review. Polish.

PMID:
10494186
18.

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R.

Ann Intern Med. 1991 Dec 15;115(12):931-5.

PMID:
1952489
19.

Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance.

Patriarca F, Fanin R, Silvestri F, Candoni A, Zaja F, Sperotto A, Geromin A, Baccarani M.

Leuk Lymphoma. 1999 Aug;34(5-6):591-6.

PMID:
10492084
20.

Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.

Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR.

Blood. 1996 Sep 1;88(5):1780-7.

Supplemental Content

Support Center